Abstract: The present invention relates to the field of biomedicine, and specifically relates to a proteolysis-targeting chimera (PROTAC) compound. The structure of the PROTAC compound can be represented by general formula LGP-LK-LGE, wherein LGP is a ligand for binding a deoxyribonucleic acid (DNA) polymerase; LGE is a ligand for binding an E3 ubiquitin ligase; and LK is a linker linking the two above ligands. The compound prevents virus replication and kills viruses by means of degrading a deoxyribonucleic acid (DNA) polymerase that inhibits the viruses, and thus performs the function of treating and intervening in viral infectious diseases such as hepatitis B and secondary diseases, and the acquired immunodeficiency syndrome.

Abstract: The present invention is based on the discovery of a proteolysis targeting compound having tissue targeting capability and use thereof, relating to medicinal products, and to such a compound or a pharmaceutically acceptable salt thereof, a stereoisomer, a solvate, or a polymorph. The compound is a proteolysis targeting chimera (PROTAC) with specific tissue targeting ability. The compound structure comprises three parts, i.e., A-BD-CON, wherein the part A is a PROTAC, one end of the structure thereof is a target protein ‘binding ligand, and the other end is a ubiquitin ligase ligand; and the part CON is a ligand of an asialoglycoprotein receptor (ASGPR), enabling the specific tissue targeting function. The compound enriches in liver tissue and is able to target cells in the tissue. The invention achieves improved druggability of the PROTAC with higher solubility and cellular membrane permeability, therefore produces enhanced pharmaceutical effect on the specific target tissue.